Key Insights

Highlights

Success Rate

83% trial completion

Published Results

247 trials with published results (16%)

Research Maturity

796 completed trials (50% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

10.5%

166 terminated out of 1581 trials

Success Rate

82.7%

-3.8% vs benchmark

Late-Stage Pipeline

8%

128 trials in Phase 3/4

Results Transparency

31%

247 of 796 completed with results

Key Signals

247 with results83% success166 terminated

Data Visualizations

Phase Distribution

1,259Total
Not Applicable (399)
Early P 1 (36)
P 1 (311)
P 2 (385)
P 3 (103)
P 4 (25)

Trial Status

Completed796
Recruiting226
Unknown180
Terminated166
Active Not Recruiting86
Withdrawn66

Trial Success Rate

82.7%

Benchmark: 86.5%

Based on 796 completed trials

Clinical Trials (1581)

Showing 20 of 20 trials
NCT07110142Not ApplicableRecruiting

Tongue Proactive Strengthening Exercise Program Following Partial/Hemi Glossectomy and Reconstruction

NCT03132922Phase 1Active Not Recruiting

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT04313504Phase 2CompletedPrimary

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

NCT06904365Recruiting

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

NCT04541381Not ApplicableSuspended

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

NCT06091930Phase 1Completed

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

NCT07101432Phase 1RecruitingPrimary

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

NCT05182229Not ApplicableActive Not RecruitingPrimary

Comparing Two Ways to Manage Head and Neck Lymphedema

NCT07528495Phase 2RecruitingPrimary

A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's

NCT05256238Not ApplicableCompletedPrimary

Effect of Exercise in Head and Neck Cancer Patients

NCT03355560Phase 2CompletedPrimary

Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy

NCT07058805Phase 2RecruitingPrimary

Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer

NCT06576908Not ApplicableCompletedPrimary

Evaluation of On-Couch CBCT Image Quality

NCT06239194Phase 1Recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT03506451Not ApplicableCompletedPrimary

PaRTNer: Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer A Pilot, Survey Based Study

NCT05984680Completed

COPD Care Pathway Among Patients With Cancer

NCT02270814Phase 2Active Not RecruitingPrimary

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma

NCT07557225Not ApplicableNot Yet Recruiting

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

NCT02641093Phase 2Active Not RecruitingPrimary

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

NCT07124000Recruiting

DESTINY-PANTUMOUR04

Scroll to load more

Research Network

Activity Timeline